A role for the RISK pathway and KATP channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart

British Journal of Pharmacology

Volumn 154, Issue 1, 2008, Pages 41-50

  Du Toit, E F ^a   Genis, A ^a   Opie, L H ^b   Pollesello, P ^c   Lochner, A ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c ORION CORPORATION   (Finland)

Author keywords

Levosimendan; Myocardial function; Myocardial infarct; Reperfusion injury; RISK pathway

Indexed keywords

5 HYDROXYDECANOIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM); GLIBENCLAMIDE; LEVOSIMENDAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOTRANSFERASE; REPERFUSION INJURY SALVAGE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENZYME ACTIVITY; ENZYME INHIBITION; GUINEA PIG; HEART FUNCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SARCOLEMMA;

EID: 42949135943     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.52     Document Type: Article

References (48)

1. Auchampach JA, Grover GJ, Gross GJ (1992). Blockade of ischaemic pre‐conditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5‐hydroxydecanoate. Cardiovasc Res 26: 1054–1062.
2. Becker LC, Ambrosio G (1987). Myocardial consequences of reperfusion. Prog Cardiovasc Dis 30: 23–44.
3. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein‐dye binding. Anal Biochem 72: 248–254.
4. Busk M, Meang M, Kistensen J, Berg JS, Mortensen UK, Nielsen TT et al. (2006). Effects of levosimendan on myocardial infarct size and hemodynamics in a closed chest porcine ischaemia–reperfusion model. Cardiovasc Drugs Ther 20: 335–342.
5. Cammarata GA, Weil MH, Sun S, Huang L, Fang X, Tang W (2006). Levosimendan improves cardiopulmonary resuscitation and survival by K(ATP) channel activation. J Am Coll Cardiol 47: 1083–1085.
6. Cleland JG, Nikitin N, McGowan J (2004). Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure. Expert Rev Cardiovasc Ther 2: 9–19.
7. Darling CE, Jiang R, Maynard M, Whittaker P, Przyklenk K (2005). Post‐conditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2. Am J Physiol Heart Circ Physiol 289: H1618–H1626.
8. Du Toit EF, Muller CA, McCarthy J, Opie LH (1999). Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischaemia/reperfusion in the Langendorff‐perfused guinea pig heart. J Pharmacol Exp Ther 290: 505–514.
9. Du Toit EF, Rossouw E, Salie R, Opie LH, Lochner A (2005). Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model. Cardiovasc Drugs Ther 19: 23–31.
10. Duygu H, Ozerkan F, Nalbantgil S, Yildiz A, Akilli A, Akin M et al. (2007). Effect of levosimendan on right systolic and diastolic functions in patients with ischaemic heart failure. Int J Clin Pract 62: 228–233.
11. Fliss H, Gattinger D (1996). Apoptosis in ischemic and reperfused rat myocardium. Circ Res 79: 949–956.
12. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K et al. (2002). Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low‐output heart failure (the LIDO study): a randomised double‐blind trial. Lancet 360: 196–202.
13. Forman MB, Virmani R, Puett DW (1990). Mechanisms of therapy of myocardial reperfusion injury. Circulation 81: IV69–IV78.
14. Garlid KD, Dos Santos P, Xie ZJ, Costa ADT, Paucek P (2003). Mitochondrial potassium transport: the role of the mitochondrial ATP‐sensitive K+ channel in cardiac function and cardioprotection. Biochim Biophys Acta 1606: 1–21.
15. Givertz MM, Andreou C, Conrad CH, Colucci WS (2007). Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alterations of force–frequency and relaxation–frequency relationships. Circulation 115: 1218–1224.
16. Gross GJ, Auchampach JA (1992). Blockade of ATP‐sensitive potassium channels prevents myocardial pre‐conditioning in dogs. Circ Res 70: 223–227.
17. Halkos ME, Kerendi F, Corvera JS, Wang NP, Kin H, Payne CS et al. (2004). Myocardial protection with post‐conditioning is not enhanced by ischaemic pre‐conditioning. Ann Thor Surg 78: 961–969.
18. Haunstetter A, Izumo S (1998). Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res 82: 1111–1129.
19. Hausenloy DJ, Yellon DM (2003). The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 35: 339–341.
20. Hausenloy DJ, Yellon DM (2004). New directions for protecting the heart against ischaemia/reperfusion injury: targeting the reperfusion injury salvage kinase (RISK) pathway. Cardiovasc Res 61: 448–460.
21. Hausenloy DJ, Tsang A, Yellon DM (2005). The reperfusion injury salvage kinase pathway: a common target for both ischaemic pre‐conditioning and post‐conditioning. Trends Cardiovasc Med 15: 69–75.
22. Hausenloy DJ, Mocanu MM, Yellon DM (2003). Activation of pro‐survival kinase cascades (PI3Kinase‐Akt‐p70S6K kinase and Erk 1/2 ‐p70S6K kinase) at reperfusion is essential for pre‐conditioning induced protection. Circulation 108: I‐288.
23. Hiayawaki H, Zhou X, Ashraf M (1996). Calcium pre‐conditioning elicits strong protection against ischaemic injury via protein kinase C signaling pathway. Circ Res 79: 137–146.
24. Kersten JR, Montgomery MW, Pagel PS, Waltier DC (2000). Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 90: 5–11.
25. Kin H, Zhao ZQ, Sun HY, Wang NP, Corvera JS, Halkos ME et al. (2004). Post‐conditioning attenuates myocardial ischaemia/reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 62: 74–85.
26. Kloner RA, Rezkalla SH (2004). Cardiac protection during acute myocardial infarction: where do we stand in 2004 ? J Am Coll Cardiol 44: 276–286.
27. Kopustinskiene DM, Pollesello P, Saris NE (2001). Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol 428: 311–314.
28. Kouchi I, Murakami T, Nawada M, Akao M, Sasayama S (1998). K ATP channels are common mediators of ischaemic and calcium pre‐conditioning in rabbits. Am J Physiol 274: H1106–H1112.
29. Lepran I, Pollesello P, Vajda S, Varro A, Papp JG (2006). Pre‐conditioning effects of levosimendan in a rabbit cardiac ischaemia–reperfusion model. J Cardiovasc Pharmacol 48: 148–152.
30. Marais E, Genade S, Salie R, Huisamen B, Lochner A (2005). The temporal relatonship between p38 MAPK and HSP27 activation in ischemic and pharmacological pre‐conditioning. Basic Res Cardiol 100: 35–47.
31. McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H et al. (1996). Recent trends in acute coronary heart disease—mortality, morbidity, medical care, and risk factors. N Eng J Med 334: 884–890.
32. Meldrum DR, Cleveland JCJ, Sheridan BC, Rowland RT, Banerjee A, Harken AH (1996). Cardiac pre‐conditioning with calcium; clinically accessible myocardial protection. J Thorac Cardiovasc Surg 112: 778–786.
33. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL et al. (2005). Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 111: 1504–1509.
34. Murray CJ, Lopez AD (1997). Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349: 1498–1504.
35. Nieminen MS, Akkila J, Hasenfuss J, Kleber FX, Lehtonen LA, Mitrovic V et al. (2000). Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36: 1903–1912.
36. Opie LH (1991). Role of calcium and other ions in reperfusion injury. Cardiovasc Drugs Ther 75: 237–247.
37. Pollesello P, Papp Z (2007). The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol 50: 257–263.
38. Rainbow RD, Norman RI, Davies NW, Standen NB (2005). Reduced effectiveness of HMR 1098 in blocking cardiac sarcolemmal K ATP channel during metabolic stress. J Mol Cel Cardiol 39: 637–646.
39. Sargento L, Brito D, Matias JS, Madeira H (2007). Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One month follow‐up. Rev Port Cardiol 26: 717–726.
40. Schwartz LM, Lagranha CJ (2006). Ischaemic post‐conditioning during reperfusion activates Akt and ERK without protecting against lethal myocardial ischaemia–reperfusion injury in pigs. Am J Physiol Heart Circ Physiol 290: H1011–H1018.
41. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I et al. (2005). Post‐conditioning the human heart. Circulation 112: 2143–2148.
42. Van Domberg RT, Sonnenschein K, Nieuwlaat R, Kamp O, Storm CJ, Bax JJ et al. (2005). Sustained benefit 20 years after reperfusion therapy in acute myocardial infarction. J Am Coll Cardiol 46: 15–20.
43. Yang XM, Krieg T, Cui L, Downey JM, Cohen MV (2004a). NECA and bradikinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK and NO. J Mol Cell Cardiol 36: 411–421.
44. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV (2004b). Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 44: 1103–1110.
45. Yellon DM, Baxter GF (1999). Reperfusion injury revisited: is there a role for growth factors signalling in limiting lethal reperfusion injury ? Trends Cardiovasc Med 9: 245–249.
46. Yellon DM, Downey JM (2003). Pre‐conditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83: 1113–1151.
47. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N (1997). The novel calcium sensitizer levosimendan activates the ATP‐sensitive K + channel in rat ventricular cells. J Pharmacol Exp Therap 283: 375–383.
48. Zao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA (2003). Inhibition of myocardial injury by ischaemic post‐conditioning during reperfusion: comparison with ischaemic pre‐conditioning. Am J Physiol 258: 579–588.